Randomized trial shows improved overall survival in advanced urothelial carcinoma, suggesting pembrolizumab may be a better choice than chemotherapy.
Pembrolizumab was associated with significantly longer overall survival (by approximately 3 months) and with a lower rate of treatment-related adverse events than chemotherapy as second-line therapy for platinum-refractory advanced urothelial carcinoma. (Funded by Merck; KEYNOTE-045 ClinicalTrials.gov number, NCT02256436 .).
No takes yet. Share an insight, caveat, or question.
Bellmunt et al. (2017) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: